DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Monday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright decreased their target price on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $0.80 on Monday. The company has a market capitalization of $77.29 million, a P/E ratio of -0.95 and a beta of 0.69. The company has a 50 day simple moving average of $1.11 and a 200-day simple moving average of $1.48. DBV Technologies has a 1 year low of $0.78 and a 1 year high of $4.04.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The company had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $3.20 million. As a group, research analysts expect that DBV Technologies will post -1.22 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.